Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.38 -0.51 (-2.05%)
Streaming Delayed Price Updated: 1:47 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
From Pacira BioSciences
Via GlobeNewswire
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
Via Chartmill
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
From Pacira BioSciences
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Via Benzinga
Earnings Preview: Pacira BioSciences
Via Benzinga
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
Analyst Expectations for Pacira BioSciences's Future
Via Benzinga
4 Analysts Have This to Say About Pacira BioSciences
Via Benzinga
Analyst Ratings for Pacira BioSciences
Via Benzinga
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
From Pacira BioSciences
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Third Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
From Pacira BioSciences
Via GlobeNewswire
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
From Pacira BioSciences
Via GlobeNewswire
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Leadership Succession Plan
From Pacira BioSciences
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
From Pacira BioSciences
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
Pacira BioSciences Reports Second Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.